- GM Removes CEO Henderson; Whitacre is Interim Chief
- Who Were the Biggest Winners And Losers This Year?
- Look Ahead: Markets Count Down to US Jobs Report
- GE, Comcast Complete Deal Over NBC Universal: Source
- US May Raise Rates Before Jobs Recover: Fed's Plosser
- Cramer: Watch Tech Stocks Wednesday
- Stocks Likely Don't Need Santa to Keep Rally Going
- Super Fantasy Christmas Gifts of 2009
- Larry Kudlow's Open Letter to Tiger Woods
- Unemployment to Peak at 10.5%: Moody's Economist
- 8 Stocks to Gain on Obama's Afghan Plan: Analysts
- BofA On Proposed Changes In The Housing Bailout Program
- The Future of The Media Landscape
- November Auto Sales Muddle Along
- Busch: What Obama Won't Say Tonight
- Stick with Equities—Avoid Emerging Markets: Laszlo Birinyi
- Pfizer Chomps On A Carrot
- Predictions 2010: Technology
- Continental reports 2.9 pct increase in traffic
- FDA approves OTC version of heartburn drug Zegerid
- Nordson promotes Pembroke to head of EFD business
- Bridgestone tire prices going up 5 percent
- SWS Group selling 4.1 million shares of stock
- ExpressJet CEO jumps to American Airlines
- Timeline of key events in career of Henderson
- Delta cutting more flights at Cincinnati
- Harley workers to vote on contract at Pa. plant
Text Size 
NEW YORK - Pfizer Inc.'s $68 billion purchase of Wyeth will close Thursday after antitrust regulators in the U.S. and Canada cleared the deal, which will make Pfizer the world's largest drugmaker by revenue.
The Federal Trade Commission approved the deal Wednesday, and Pfizer said the Canadian Competition Bureau also gave its blessing. Pfizer will have to sell about half of Wyeth's animal health business and change a Canadian distribution agreement, and the company said it will also sell its horse vaccine business.
German drugmaker Boehringer Ingelheim will buy those divisions, including Wyeth's vaccines for cattle, dogs, and cats, and medicines used in treating cattle, dogs, cats, and horses.
The sale will pump up the sales and pipeline of New York-based Pfizer by giving it Madison, N.J.-based Wyeth's biotechnology drugs and vaccines like Prevnar. Its top selling drugs include the antidepressant Effexor, and Enbrel for rheumatoid arthritis.
Wyeth shares rose 43 cents to $49.59 in afternoon trading, and hit an annual high of $49.90. Pfizer stock added 15 cents to $16.93.
Print
Email
- Will the Fed raise rates? Will the dollar continue its slide? CNBC experts weigh in on the year ahead.
- Goldman Sachs has forbidden employees from gathering in private holiday parties of 12 or more.
- Do you have what it takes to run your own business? Ask yourself these questions.
- Heavily armed pirates in Somalia have set up a sort of stock exhange to fund their hijackings.
- Since its launch in 1998, Google has become a primary force on the Internet. How much do you know about the company?
- A famed author has written all his work on an old typewriter that is now up for auction. The NYT reports.
Data is a real-time snapshot *Data is delayed at least 15 minutes